A FAERS analysis found safety signals involving propofol and midazolam. Its reporting-odds ratios describe patterns among submitted reports, not the probability that a treated patient will experience an event.
The analysis performed
Wei and colleagues examined reports from the first quarter of 2004 through the first quarter of 2025. They used disproportionality methods, onset-time analyses, and exploratory mechanistic approaches for single-drug and combined exposure reports.
The paper identified signals including propofol infusion syndrome and anaphylactic shock. Some reporting-odds ratios were very large. Those values must remain attached to the spontaneous-reporting framework and its chosen comparison groups.
Why a signal is not a causal rate
FAERS does not provide a complete denominator of all exposed patients. Underreporting, selective reporting, duplicates, indication, illness severity, and co-medications can affect the pattern. Comparing signal magnitudes does not establish that a combination reduces or increases true clinical risk by the same ratio.
The authors expressly characterize their findings as hypothesis-generating associations. Proposed pathway findings also require additional work and do not demonstrate an allergic mechanism in an individual patient.
Application to a disputed event
Use the paper to identify an issue worth investigating, then reconstruct the clinical chronology and alternative causes. Do not turn a reported signal into an incidence estimate or use it alone to attribute a specific collapse or infusion syndrome to the combination.
Source paper
Original analysis of the supplied journal article, identified as PMC13235193.
Leave a Reply